p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 605-610

  Montenarh, M ^a   Harlozinska A ^b   Bar, J K ^b   Kartarius, S ^a   Gunther J ^a   Sedlaczek, P ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Autoantibodies; Body fluids; Ovarian cancer; P53

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ARTICLE; ASCITES FLUID; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; SERUM; TUMOR DIFFERENTIATION;

EID: 0031824256     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.605     Document Type: Article

References (43)

1. Hall PA and Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited. J Pathol 172: 1-4, 1994.
2. Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinic - An abridged historical perspective. Carcinogenesis 17: 1187-1198, 1996.
3. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK and Iacopetta BJ: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27: 1050-1055, 1996.
4. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
5. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994.
6. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M and Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma - Correlation with clinicopathologic features and survival. Cancer 78: 2146-2152, 1996.
7. Angelopoulou K, Stratis M and Diamandis EP: Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70: 46-51, 1997.
8. Collet B, Raoul J-L, Le Berre N, Heresbach D, Meritte H, Quillien V and De Certaines J-D: Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: Comparison with p53 alterations and lymph node invasion. Int J Oncol 11: 617-621, 1997.
9. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Brand A, van de Velde CJH and Melief CJM: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637-641, 1995.
10. Montenarh M and Götz C: p53 autoantibodies and human malignancies. Cancer Mol Biol 4: 991-1010, 1997.
11. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Viñolas N, Resell R, Torà M, Real FX, Posner JB and Dalmau J: Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 89: 381-385, 1997.
12. Soussi T: The humoral response to the tumor-suppressor geneproduct p53 in human cancer: Implications for diagnosis and therapy. Immunol Today 17: 354-356, 1996.
13. Von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VMG, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N and Trivers GE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56: 4917-4921, 1996.
14. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
15. Rainov NG, Dobberstein K-U, Fittkau M, Bahn H, Holzhausen H-J, Gantchev L and Burkert W: Absence of p53 autoantibodies in sera from glioma patients. Clin Cancer Res 1: 775-781, 1995.
16. Wild CP, Ridanpää M, Anttila S, Lubin R Soussi T, Husgafvel-Pursiainen K and Vainio H: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 64: 176-181, 1995.
17. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, Humphrey P, Berchuck A, Ponder BAJ and Bast RC Jr. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84: 1793-1798, 1992.
18. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S and Hirohashi S: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 83: 978-984, 1992.
19. Kohler MF, Kerns B-JM, Humphrey PA, Marks JR, Bast RC Jr and Berchuck A: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81: 643-650, 1993.
20. Kohler MF, Marks JR, Wiseman RW, Jacobs JJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr and Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519, 1993.
21. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA and Yandell DW: p53 Gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965, 1993.
22. Lee JH, Kang YS, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Kavanagh JJ and Wharton JT: p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 85: 43-50, 1995.
23. Mazars R, Pujol P, Maudelonde T, Jeanteur P and Theillet C: p53 Mutations in ovarian cancer A late event. Oncogene 6: 1685-1690, 1991.
24. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE and Haites NE: p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53: 2128-2132, 1993.
25. Niva K, Itoh M, Murase T, Morishita S, Itoh N, Mori H and TamayaT: Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 70: 1191-1197, 1995.
26. Ellabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR and Blumenson LE: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80: 892-898, 1997.
27. Harlozinska A and Bar JK: Relationship between p53 and c-erbB-2 overexpression in tissue sections and cyst fluid cells of patients with ovarian cancer. Tumor Biol 15: 223-229, 1994.
28. Harlozinska A, Bar JK, Sedlaczek P and Gerber J: Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms - Correlation with histopathology. Am J Clin Pathol 105: 334-340, 1996.
29. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonspn JH, Grill JP, Su JQ, Katzmann JA and Roche PC: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64-69, 1994.
30. Klemi PJ, Pylkkänen L, Kiilholma P, Kurvinen K and Joensuu H: P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201-1208, 1995.
31. Green JA, Robertson LJ, Campbell IR and Jenkins J: Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: Correlation with differentiation. Cancer Detect Prev 19: 151-155, 1995.
32. Vennegoor CJGM, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RHM, Kast WM, Melief CJM and Kenemans P: Autoantibodies to p53 in ovarian cancer patients and healthy women: A comparison between whole p53 protein, and 18-mer peptides for screening purposes. Cancer Lett 116: 93-101, 1997.
33. Harlozinska A, Bar JK, Cislo M, Richter R and Rabczynski J: Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms. Anal Cell Pathol 4: 1-12, 1992.
34. Harlow E, Crawford LV, Pim DC and Williamson NM: Monoclonal antibodies specific for the SV40 tumor antigens. J Virol 39: 861-869, 1981.
35. Lang P, Maurer J, Höher D, Bomhöft G, Montenarh M, Berdel W, Thiel E and Kreuser E-D: Mutation and expression of the p53 tumor suppressor gene in tumor samples and cancer cell lines: comparison of non-isotopic direct DNA-sequencing, immunoblotting and immunohistochemistry. Int J Oncol 2: 347-355, 1993.
36. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E and May P: Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 4: 1483-1488, 1989.
37. Appel K, Wagner P, Boldyreff B, Issinger O-G and Montenarh M: Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory ß-subunit of protein kinase CK2. Oncogene 11: 1971-1978, 1995.
38. Montenarh M, Kohler M and Henning R: Oligomerization of simian virus 40 large T antigen is not necessarily repressed by temperature-sensitive A gene lesions. J Virol 49: 658-664, 1984.
39. Schlichtholz B, Trédaniel J, Lubin R, Zalcman G, Hirsch A and Soussi T: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809-816, 1994.
40. Davidoff AM, Iglehart JD and Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442, 1992.
41. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Trédaniel J, Hirsch A, Caron de Fromentel CC, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B and Soussi T: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872-5876, 1993.
42. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
43. Angelopoulou K and Diamandis EP: Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer (A) 33A: 115-121, 1997.